Ellume announces another global partnership – this time with QIAGEN on the detection of tuberculosis

  • On January 8, 2019
Highlights Australia’s Ellume Limited has partnered with QIAGEN N.V. to bring the next generation of latent TB testing to low-resource, high-burden countries The deal includes the licensing of Ellume technologies and a USD $15M minority investment by QIAGEN in Ellume Limited This announcement builds on the recent announcement of a global partnership with GlaxoSmithKline announced […]
Read More

Medical diagnostics firm Ellume gets German backing for TB testing

  • On January 7, 2019
7 January 2019, Peter Williams This article originally appeared in The Australian, print and online, on 7th January 2019. View the original here on The Australian Website. Brisbane medical diagnostics company Ellume has received a $US15 million ($21m) investment from German biotech Qiagen as part of a broader strategic partnership between the two companies to detect tuberculosis. Clinical trials for a […]
Read More